Abstrakt

Przypisy

• 1. Agewall S., Norman B.: Association between AMPD1 gene polymorphismand coagulation factors in patients with coronary heartdisease. Pathophysiol. Haemost. Thromb., 2006; 35: 440-444 2 Albert C.M., Ma J., Rifai N., Stampfer M.J., Ridker P.M.: Prospectivestudy of C-reactive protein, homocysteine, and plasma lipid levels aspredictors of sudden cardiac death. Circulation, 2002; 105: 2595-2599
  Google Scholar
• 2. allele of the adenosinedeaminase gene may protect against coronary artery disease. Cardiology,2007; 108: 275-281
  Google Scholar
• 3. Anand S.S., Yusuf S.: C-reactive protein is a bystander of cardiovasculardisease. Eur. Heart J., 2010; 31: 2092-2096
  Google Scholar
• 4. Apostolakis S., Vogiatzi K., Krambovitis E., Spandidos D.A.: IL-1cytokines in cardiovascular disease: diagnostic, prognostic and therapeuticimplications. Cardiovasc. Hematol. Agents Med. Chem.,2008; 6: 150-158
  Google Scholar
• 5. Barron H.V., Cannon C.P., Murphy S.A., Braunwald E., Gibson C.M.:Association between white blood cell count, epicardial blood flow,myocardial perfusion, and clinical outcomes in the setting of acutemyocardial infarction: a thrombolysis in myocardial infarction 10substudy. Circulation, 2000; 102: 2329-2334
  Google Scholar
• 6. Biasucci L.M., Bellocci F., Landolina M., Rordorf R., Vado A., MenardiE., Giubilato G., Orazi S., Sassara M., Castro A., Massa R., KheirA., Zaccone G., Klersy C., Accardi F., Crea F.: Risk stratification ofischaemic patients with implantable cardioverter defibrillators byC-reactive protein and a multi-markers strategy: results of the CAMI-GUIDE study. Eur. Heart J., 2012; 33: 1344-1350
  Google Scholar
• 7. Blangy H., Sadoul N., Dousset B., Radauceanu A., Fay R., Aliot E.,Zannad F.: Serum BNP, hs-C-reactive protein, procollagen to assessthe risk of ventricular tachycardia in ICD recipients after myocardialinfarction. Europace, 2007; 9: 724-729
  Google Scholar
• 8. Blum A.: White blood cell count and the coronary anatomy inacute coronary events. Am. J. Cardiol., 2005; 95: 159-160
  Google Scholar
• 9. Bochner B.S., Luscinskas F.W., Gimbrone M.A.Jr., Newman W.,Sterbinsky S.A., Derse-Anthony C.P., Klunk D., Schleimer R.P.: Adhesionof human basophils, eosinophils, and neutrophils to interleukin1-activated human vascular endothelial cells: contributions of endothelialcell adhesion molecules. J. Exp. Med., 1991; 173: 1553-1557
  Google Scholar
• 10. Boos C.J., Anderson R.A., Lip G.Y.: Is atrial fibrillation an inflammatorydisorder? Eur. Heart J., 2006; 27: 136-149
  Google Scholar
• 11. Burke A.P., Tracy R.P., Kolodgie F., Malcom G.T., Zieske A., KutysR., Pestaner J., Smialek J., Virmani R.: Elevated C-reactive protein valuesand atherosclerosis in sudden coronary death: association withdifferent pathologies. Circulation, 2002; 105: 2019-2023
  Google Scholar
• 12. Cannon C.P., McCabe C.H., Wilcox R.G., Bentley J.H., BraunwaldE.: Association of white blood cell count with increased mortalityin acute myocardial infarction and unstable angina pectoris. OPUS–TIMI 16 Investigators. Am. J. Cardiol., 2001; 87: 636-639
  Google Scholar
• 13. Capuano V., Lamaida N., De Martino M., Mazzotta G.: Associationbetween white blood cell count and risk factors of coronary arterydisease. G. Ital. Cardiol., 1995; 25: 1145-1152
  Google Scholar
• 14. Chapman M.J., Sposito A.C.: Hypertension and dyslipidaemiain obesity and insulin resistance: pathophysiology, impact on atheroscleroticdisease and pharmacotherapy. Pharmacol. Ther., 2008;117: 354-373
  Google Scholar
• 15. Chen J., Jin J., Song M., Dong H., Zhao G., Huang L.: C-reactiveprotein down-regulates endothelial nitric oxide synthase expressionand promotes apoptosis in endothelial progenitor cells through receptorfor advanced glycation end-products. Gene, 2012; 496: 128-135
  Google Scholar
• 16. Cronstein B.N.: Adenosine, an endogenous anti-inflammatoryagent. J. Appl. Physiol., 1994; 76: 5-13
  Google Scholar
• 17. D’Alessandris C., Lauro R., Presta I., Sesti G.: C-reactive protein inducesphosphorylation of insulin receptor substrate-1 on Ser307 andSer612 in L6 myocytes, thereby impairing the insulin signalling pathwaythat promotes glucose transport. Diabetologia, 2007; 50: 840-849
  Google Scholar
• 18. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R.: Metabolicsyndrome: a comprehensive perspective based on interactions betweenobesity, diabetes, and inflammation. Circulation, 2005; 111: 1448-1454
  Google Scholar
• 19. Dent T.H.: Predicting the risk of coronary heart disease. I. Theuse of conventional risk markers. Atherosclerosis, 2010; 213: 345-351
  Google Scholar
• 20. Dent T.H.: Predicting the risk of coronary heart disease. II. Therole of novel molecular biomarkers and genetics in estimating risk,and the future of risk prediction. Atherosclerosis, 2010; 213: 352-362
  Google Scholar
• 21. Di Bella G., Siciliano V., Aquaro G.D., Molinaro S., Lombardi M.,Carerj S., Landi P., Rovai D., Pingitore A.: Scar extent, left ventricularend-diastolic volume, and wall motion abnormalities identify highriskpatients with previous myocardial infarction: a multiparametricapproach for prognostic stratification. Eur. Heart J., 2013; 34: 104-111
  Google Scholar
• 22. Dinarello C.A.: Immunological and inflammatory functions ofthe interleukin-1 family. Annu. Rev. Immunol., 2009; 27: 519-550
  Google Scholar
• 23. Elmas E., Hölzer L., Lang S., Popp T., Kälsch T., Wolpert C., BrueckmannM., Borggrefe M.: Enhanced proinflammatory response ofmononuclear cells to in vitro LPS-challenge in patients with ventricularfibrillation in the setting of acute myocardial infarction.Cytokine, 2008; 43: 138-142
  Google Scholar
• 24. Espinola-Klein C., Gori T., Blankenberg S., Munzel T.: Inflammatorymarkers and cardiovascular risk in the metabolic syndrome.Front. Biosci., 2011; 16: 1663-1674
  Google Scholar
• 25. Executive Summary of The Third Report of The National CholesterolEducation Program (NCEP) Expert Panel on Detection, Evaluation,And Treatment of High Blood Cholesterol In Adults (AdultTreatment Panel III). JAMA, 2001; 285: 2486-2497
  Google Scholar
• 26. Festa A., D’Agostino R. Jr., Howard G., Mykkänen L., Tracy R.P.,Haffner S.M.: Chronic subclinical inflammation as part of the insulinresistance syndrome: the Insulin Resistance Atherosclerosis Study(IRAS). Circulation, 2000; 102: 42-47
  Google Scholar
• 27. Flevari P., Theodorakis G., Leftheriotis D., Kroupis C., KolokathisF., Dima K., Anastasiou-Nana M., Kremastinos D.: Serum markers ofderanged myocardial collagen turnover: their relation to malignantventricular arrhythmias in cardioverter-defibrillator recipients withheart failure. Am. Heart J., 2012; 164: 530-537
  Google Scholar
• 28. Guo Y., Lip G.Y., Apostolakis S.: Inflammation in atrial fibrillation.J. Am. Coll. Cardiol., 2012; 60: 2263-2270
  Google Scholar
• 29. Hansson G.K.: Inflammation, atherosclerosis, and coronary arterydisease. N. Engl. J. Med., 2005; 352: 1685-1695
  Google Scholar
• 30. Hu F.B., Meigs J.B., Li T.Y., Rifai N., Manson J.E.: Inflammatorymarkers and risk of developing type 2 diabetes in women. Diabetes,2004; 53: 693-700
  Google Scholar
• 31. International Diabetes Federation: The IDF consensus worldwidedefinition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf (13.10.2015)
  Google Scholar
• 32. Kanda T., Takahashi T.: Interleukin-6 and cardiovascular diseases.Jpn. Heart J., 2004; 45: 183-193
  Google Scholar
• 33. Kaneko H., Anzai T., Naito K., Kohno T., Maekawa Y., TakahashiT., Kawamura A., Yoshikawa T., Ogawa S.: Role of ischemic preconditioningand inflammatory response in the development of malignantventricular arrhythmias after reperfused ST-elevation myocardialinfarction. J. Card. Fail., 2009; 15: 775-781
  Google Scholar
• 34. Konstantino Y., Kusniec J., Reshef T., David-Zadeh O., Mazur A.,Strasberg B., Battler A., Haim M.: Inflammatory biomarkers are notpredictive of intermediate-term risk of ventricular tachyarrhythmiasin stable CHF patients. Clin. Cardiol., 2007; 30: 408-413
  Google Scholar
• 35. Kourliouros A., Savelieva I., Kiotsekoglou A., Jahangiri M., CammJ.: Current concepts in the pathogenesis of atrial fibrillation. Am.Heart J., 2009; 157: 243-252
  Google Scholar
• 36. Loppnow H., Werdan K., Buerke M.: Vascular cells contribute toatherosclerosis by cytokine- and innate-immunity-related inflammatorymechanisms. Innate Immun., 2008; 14: 63-87
  Google Scholar
• 37. Madjid M., Fatemi O.: Components of the complete blood countas risk predictors for coronary heart disease: in-depth review andupdate. Tex. Heart Inst. J., 2013; 40: 17-29
  Google Scholar
• 38. Mathieu P., Lemieux I., Després J.P.: Obesity, inflammation, andcardiovascular risk. Clin. Pharmacol. Ther., 2010; 87: 407-416
  Google Scholar
• 39. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., VanWagoner D.R., Bauer J.A.: Impaired myofibrillar energetics and oxidativeinjury during human atrial fibrillation. Circulation, 2001;104: 174-180
  Google Scholar
• 40. Mountantonakis S., Deo R.: Biomarkers in atrial fibrillation,ventricular arrhythmias, and sudden cardiac death. Cardiovasc.Ther., 2012; 30: e74-e80
  Google Scholar
• 41. Nakanishi N., Sato M., Shirai K., Nakajima K., Murakami S., TakatorigeT., Suzuki K., Tatara K.: Associations between white blood cellcount and features of the metabolic syndrome in Japanese male officeworkers. Ind. Health, 2002; 40: 273-277
  Google Scholar
• 42. Nilsson G., Hedberg P., Jonason T., Lönnberg I., Tenerz A., OhrvikJ.: White blood cell counts associate more strongly to the metabolicsyndrome in 75-year-old women than in men: a population basedstudy. Metab. Syndr. Relat. Disord., 2007; 5: 359-364
  Google Scholar
• 43. Pedersen B.K., Febbraio M.A.: Muscle as an endocrine organ:focus on muscle-derived interleukin-6. Physiol. Rev., 2008; 88: 1379-1406
  Google Scholar
• 44. Rana J.S., Boekholdt S.M., Ridker P.M., Jukema J.W., Luben R.,Bingham S.A., Day N.E., Wareham N.J., Kastelein J.J., Khaw K.T.: Differentialleucocyte count and the risk of future coronary arterydisease in healthy men and women: the EPIC-Norfolk ProspectivePopulation Study. J. Intern. Med., 2007; 262: 678-689
  Google Scholar
• 45. Rana J.S., Nieuwdorp M., Jukema J.W., Kastelein J.J.: Cardiovascularmetabolic syndrome – an interplay of, obesity, inflammation,diabetes and coronary heart disease. Diabetes Obes. Metab., 2007;9: 218-232
  Google Scholar
• 46. Ridker P.M., Buring J.E., Cook N.R., Rifai N.: C-reactive protein,the metabolic syndrome, and risk of incident cardiovascular events:an 8-year follow-up of 14 719 initially healthy American women.Circulation, 2003; 107: 391-397
  Google Scholar
• 47. Safranow K., Czyzycka E., Binczak-Kuleta A., Rzeuski R., SkowronekJ., Wojtarowicz A., Jakubowska K., Olszewska M., LoniewskaB., Kaliszczak R., Kornacewicz-Jach Z., Ciechanowicz A., ChlubekD.: Association of C34T AMPD1 gene polymorphism with featuresof metabolic syndrome in patients with coronary artery disease orheart failure. Scand. J. Clin. Lab. Invest., 2009; 69: 102-112
  Google Scholar
• 48. Safranow K., Dziedziejko V., Rzeuski R., Czyzycka E., WojtarowiczA., Bińczak-Kuleta A., Jakubowska K., Olszewska M., CiechanowiczA., Kornacewicz-Jach Z., Machaliński B., Pawlik A., Chlubek D.: Plasma concentrations of TNF-α and its soluble receptors sTNFR1 andsTNFR2 in patients with coronary artery disease. Tissue Antigens,2009; 74: 386-392
  Google Scholar
• 49. Safranow K., Rzeuski R., Binczak-Kuleta A., Czyzycka E., SkowronekJ., Jakubowska K., Wojtarowicz A., Loniewska B., CiechanowiczA., Kornacewicz-Jach Z., Chlubek D.: ADA
  Google Scholar
• 50. Sajadieh A., Nielsen O.W., Rasmussen V., Ole Hein H., HansenJ.F.: Increased ventricular ectopic activity in relation to C-reactiveprotein, and NT-pro-brain natriuretic peptide in subjects with no apparentheart disease. Pacing Clin. Electrophysiol., 2006; 29: 1188-1194
  Google Scholar
• 51. Schulze M.B., Rimm E.B., Li T., Rifai N., Stampfer M.J., Hu F.B.:C-reactive protein and incident cardiovascular events among menwith diabetes. Diabetes Care, 2004; 27: 889-894
  Google Scholar
• 52. Streitner F., Kuschyk J., Veltmann C., Brueckmann M., StreitnerI., Brade J., Neumaier M., Bertsch T., Schumacher B., Borggrefe M.,Wolpert C.: Prospective study of interleukin-6 and the risk of malignantventricular tachyarrhythmia in ICD-recipients – a pilot study.Cytokine, 2007; 40: 30-34
  Google Scholar
• 53. Streitner F., Kuschyk J., Veltmann C., Ratay D., Schoene N., StreitnerI., Brueckmann M., Schumacher B., Borggrefe M., Wolpert C.:Role of proinflammatory markers and NT-proBNP in patients withan implantable cardioverter-defibrillator and an electrical storm.Cytokine, 2009; 47: 166-172
  Google Scholar
• 54. Sutherland J.P., McKinley B., Eckel R.H.: The metabolic syndromeand inflammation. Metab. Syndr. Relat. Disord., 2004; 2: 82-104
  Google Scholar
• 55. Theuns D.A., Smith T., Szili-Torok T., Muskens-Heemskerk A.,Janse P., Jordaens L.: Prognostic role of high-sensitivity C-reactiveprotein and B-type natriuretic peptide in implantable cardioverterdefibrillatorpatients. Pacing Clin. Electrophysiol., 2012; 35: 275-282
  Google Scholar
• 56. Tong P.C., Lee K.F., So W.Y., Ng M.H., Chan W.B., Lo M.K., ChanN.N., Chan J.C.: White blood cell count is associated with macro- andmicrovascular complications in Chinese patients with type 2 diabetes.Diabetes Care, 2004; 27: 216-222
  Google Scholar
• 57. Van Snick J.: Interleukin-6: an overview. Annu. Rev. Immunol.,1990; 8: 253-278
  Google Scholar
• 58. Wu K.C., Gerstenblith G., Guallar E., Marine J.E., Dalal D., ChengA., Marbán E., Lima J.A., Tomaselli G.F., Weiss R.G.: Combined cardiacmagnetic resonance imaging and C-reactive protein levels identifya cohort at low risk for defibrillator firings and death. Circ. Cardiovasc.Imaging, 2012; 5: 178-186
  Google Scholar

Pełna treść artykułu